Role of molecular studies in the classification of lymphoma

Expert Review of Molecular Diagnostics

Volumn 4, Issue 1, 2004, Pages 83-97

  Bagg, Adam ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Classification; Diagnosis; Lymphoid leukemia; Lymphoma; Microarray; Molecular genetics; Pronosis; Targeted therapy

Indexed keywords

B CELL LYMPHOMA; CANCER CLASSIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HODGKIN DISEASE; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; ONCOGENE; T CELL LYMPHOMA; TECHNOLOGY;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; CYTOGENETIC ANALYSIS; HUMANS; LYMPHOMA; PROTEIN ARRAY ANALYSIS;

EID: 0347762804     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.1.83     Document Type: Conference Paper

References (102)

1. Isaacson PG. The current status of lymphoma classification. Br. J. Haematol. 109(2), 258-266 (2000). Insightful overview of lymphoma classification: past and present.
2. Willis RA. The tumours of lymphoid tissue. In: Pathology of Tumors. Mosby, MO, USA, 760 (1948).
3. Hopwood AT. Proceedings of the Linnean Society of London. 171, 230-234 (1957).
4. Teller E. Conversations on the Dark Secrets of Physics. Plenum Press, NY, USA (1991).
5. Anonymous National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49(10), 2112-2135 (1982).
6. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2001). Most recent and current bible of lymphoma classification.
7. Gleissner B, Thiel E. Detection of immunoglobulin heavy chain gene rearrangements in hematologic malignancies. Expert Rev. Mol. Diagn. 1(2), 191-200 (2001).
8. Wood GS. Analysis of clonality in cutaneous T-cell lymphoma and associated diseases. Ann. NY Acad. Sci. 941, 26-30 (2001).
9. Bagg A. Commentary: minimal residual disease: how low do we go? Mol. Diagn. 6(3), 155-160 (2001).
10. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 4(1), 22-29 (2003).
11. Greiner T, Armitage JO, Gross TG. Atypical lymphoproliferative diseases. Hematology (Am Soc. Hematol. Educ. Program) 133-146 (2000).
12. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000). First paradigrnatic unsupervised study using microarray analysis in lymphoma, identifying two histogenic and prognostically relevant subsets.
13. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med. 8(1), 68-74 (2002). First paradigmatic supervised study using microarray analysis in lymphoma that was able to predict response to therapy.
14. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25), 1937-1947 (2002). An extension of [12] with further genomic and expression profile correlates.
15. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B-cell lymphoma identifies a clinically favorable subgroup of diffuse large B-cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198(6), 851-862 (2003).
16. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood 96(13), 4328-4334 (2002).
17. Nanjangud G, Rao PH, Hegde A et al. Spectral karyotyping identifies new rearrangements, translocations and clinical associations in diffuse large B-cell lymphoma. Blood 99(7), 2554-2561 (2002).
18. Chaganti RS, Nanjangud G, Schmidt H, Teruya-Feldstein J. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin. Hematol. 37(4), 396-411 (2000).
19. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 77(7), 1508-1515 (1991).
20. Dyomin VG, Palanisamy N, Lloyd KO et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95(8), 2666-2671 (2000).
21. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood 95(9), 2930-2936 (2000).
22. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 101(2), 433-440 (2003).
23. Albagli-Curiel O. Ambivalent role of BCL6 in cell survival and transformation. Oncogene 22(4), 507-516 (2003).
24. Lossos IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98(4), 945-951 (2001).
25. Akasaka T, Ueda C, Kurata M et al. Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood 96(8), 2907-2909 (2000).
26. Pasqualucci L, Migliazza A, Ye BH, Dalla-Favera R. Transcriptional deregulation of mutated BCL6 alleles by loss of negative autoregulation in diffuse large B-cell lymphoma. Ann. NY Acad Sci. 987, 314-315 (2003). Details the mutational events dysregulating BCL-6 in the genetic pathogenesis of diffuse large B-cell lymphoma.
27. Pasqualucci L, Neumeister P, Goossens T et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412(6844), 341-346 (2001).
28. Dyer MJ, Oscier DG. The configuration of the immunoglobulin genes in B-cell chronic lymphocytic leukemia. Leukemia 16(6), 973-984 (2002). Good review of the role of IgH somatic hypermutation in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
29. Jelinek DF, Tschumper RC, Geyer SM et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haemtol. 115(4), 854-861 (2001).
30. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J. Exp. Med. 194(11), 1639-1647 (2001).
31. Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B-cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B-cells. J. Exp. Med. 194(11), 1625-1638 (2001). This and [30] are microarray studies which led to the recognition that both forms of CLL/SLL are closely related, have a profile of memory B-cells and the former identified the discriminating role of ZAP-70 expression.
32. McCarthy H, Wierda WG, Barron LL et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood 101(12), 4903-4908 (2003).
33. Tobin G, Thunberg U, Johnson A et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99(6), 2262-2264 (2002).
34. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 101(12), 4944-4951 (2003).
35. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000).
36. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16(6), 993-1007 (2002). Comprehensive review of genetic abnormalities in CLL/SLL.
37. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad Sci. USA 99(24), 15524-15529 (2002).
38. Yabumoto K, Akasaka T, Muramatsu M et al. Rearrangement of the 5′ cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases. Leukemia 10(6), 970-977 (1996).
39. Gaidano G, Newcomb EW, Gong JZ et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am. J. Pathol. 144(6), 1312-1319 (1994).
40. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 4(3), 211-218 (2003).
41. Aster JC, Longtine JA. Detection of BCL2 rearrangements in follicular lymphoma. Am. J. Pathol. 160(3), 759-763 (2002). Impressive summary of the state of the art in molecular diagnosis of follicular lymphoma (FL).
42. Gribben JG. Monitoring disease in lymphoma and CLL patients using molecular techniques. Best Pract. Res. Clin. Haematol. 15(1), 179-195 (2002).
43. Bagg A, Braziel RM, Arber DA, Bijwaard KE, Chu AY. Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays. J. Mol. Diagn. 4(2), 81-89 (2002).
44. Lopez-Guillermo A, Cabanillas F, McDonnell TI et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93(9), 3081-3087 (1999).
45. Albinger-Hegyi A, Hochreutener B, Abdou MT et al. High frequency of t(14;18) translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am. J. Pathol. 160(3), 823-832 (2002).
46. Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 99(12), 4265-4275 (2002). Comprehensive and interesting review of the apparent ethnic differences in the molecular etiology of FL.
47. Horsman DE, Okamoto I, Ludkovski O et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br. J. Haemtol. 120(3), 424-433 (2003).
48. Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 101(3), 1149-1154 (2003).
49. Storz MN, Van De Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. Gene expression profiles of cutaneous B-cell lymphoma. J. Invest. Dermatol. 120(5), 865-870 (2003).
50. Mintzer D, Bagg A. Clinical syndromes of transformation in clonal hematologic disorders. Am. J. Med. 111(6), 480-488 (2001).
51. Martinez-Climent JA, Alizadeh AA, Segraves R et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101(8), 3109-3117 (2003).
52. Lossos IS, Alizadeh AA, Diehn M et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl Acad. Sci. USA 99(13), 8886-8891 (2002).
53. Elenitoba-Johnson KS, Jenson SD, Abbott RT et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl Acad. Sci. USA 100(12), 7259-7264 (2003). Insightful analysis of paired FL and their transformed components, with in vitro and in vivo documentation of the role of targeted therapy.
54. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102(4), 1443-1448 (2003).
55. Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, de Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod. Pathol. 15(5), 517-525 (2002).
56. Thomazy VA, Luthra R, Uthman MO, Davies PJ, Medeiros LJ. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas. J. Mol. Diagn. 4(4), 201-208 (2002).
57. Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2), 185-197 (2003). Yet another in the series of key studies emanating from the Lymphoma/Leukemia Molecular Profiling Project.
58. Roue G, Krieger S, Florent M et al. Expression of the two alternative [A] and [B] transcripts of CCND1 gene in cyclin D1-expressing B-malignancies: relevance for the pathogenesis. Leukemia 17(3), 652-655 (2003).
59. Dreyling MH, Bullinger L, Ott G et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 57(20), 4608-4614 (1997).
60. Pinyol M, Hernandez L, Cazorla M et al. Deletions and loss of expression of p 16INK4a and p21 Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89(1), 272-280 (1997).
61. Quintanilla-Martinez L, Davies-Hill T, Fend F et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mande cell lymphoma (MCL): implications for pathogenesis. Blood 101(8), 3181-3187 (2003).
62. Fang NY, Greiner TC, Weisenburger DD et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc. Natl Acad. Sci. USA 100(9), 5372-5377 (2003).
63. Nagy B, Lundan T, Larramendy ML et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br. J. Haematol. 120(3), 434-441 (2003).
64. Walsh SH, Thorselius M, Johnson A et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 101 (10), 4047-4054 (2003).
65. Kienle D, Krober A, Katzenberger T et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics and outcome. Blood 102(8), 3003-3009 (2003).
66. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non-nodal disease. Blood 101(12), 4975-4981 (2003).
67. Camacho FI, Algara P, Rodriguez A et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 101(10), 4042-4046 (2003).
68. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma: an update on recent advances. Histopathology 40(2), 117-126 (2002). Comprehensive and up-to-date review of the genetics of marginal zone lymphoma.
69. Dogan A, Isaacson PG. Splenic marginal zone lymphoma. Semin. Diagn. Pathol. 20(2), 121-127 (2003).
70. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 97(11), 3552-3558 (2001).
71. Dierlamm J, Baens M, Wlodarska I et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93(11), 3601-3609 (1999).
72. Streubel B, Lamprecht A, Dierlamm J et al. t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101(6), 2335-2339 (2003).
73. Willis TG, Jadayel DM, Du MQ et al. Bcl-10 is involved in t(1;14)(p22;q32) of MALT B-cell lymphoma and mutated in multiple tumor types. Cell 96(1), 35-45 (1999).
74. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357(9249), 39-40 (2001). Providing a rationale for molecular testing in gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
75. Starostik P, Patzner J, Greiner A et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99(1), 3-9 (2002). Elegant genomic dissection of MALT lymphomas, revealing divergent genetic pathways.
76. Okabe M, Inagaki H, Ohshima K et al. API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Am. J. Pathol. 162(4), 1113-1122 (2003).
77. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B-cell types. Am. J. Pathol. 161(1), 81-88 (2002).
78. Kuppets R, Schwering I, Brauninger A, Rajewsky K, Hansmann ML. Biology of Hodgkin's lymphoma. Ann. Oncol. 13(Suppl. 1), 11-18 (2002). Wonderful synopsis of the elegant single cell studies emanating from these authors' laboratories.
79. Pileri SA, Ascani S, Leoncini L et al. Hodgkin's lymphoma: the pathologist's viewpoint. J. Clin. Pathol. 55(3), 162-176 (2002).
80. Kuppers R, Klein U, Schwering I et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111(4), 529-537 (2003).
81. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab. Invest. 78(3), 229-235 (1998).
82. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Ann. Oncol. 13(Suppl. 4), 147-152 (2002). Insightful summary of the mechanisms underlying the development of Hodgkin lymphoma.
83. Jungnickel B, Staratschek-Jox A, Brauninger A et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J. Exp. Med. 191(2), 395-402 (2000). First documentation of a novel mutational event in Hodgkin lymphoma.
84. Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P. The role of Epstein-Barr virus in neoplastic transformation. Oncology 60(4), 289-302 (2001).
85. Muschen M, Re D, Brauninger A et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. 60(20), 5640-5643 (2000).
86. Barth TF, Martin-Subero JI, Joos S et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101(9), 3681-3686 (2003).
87. Wlodarska I, Nooyen P, Maes B et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 101(2), 706-710 (2003).
88. + lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br. J. Haematol. 113(2), 275-295 (2001). Informative summary of the state of the art in this lymphoma, from authors whose contributions to this have been paramount.
89. Cheuk W, Chan JK. Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence. Pathology 33(1), 7-12 (2001).
90. Rassidakis GZ, Jones D, Thomaides A et al. Apoptotic rate in periphetal T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am. J. Clin. Pathol. 118(3), 328-334 (2002).
91. Villalva C, Trempat P, Greenland C et al. Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br. J. Haematol. 18(3), 791-798 (2002).
92. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects: a review. J. Pathol. 200(1), 4-15 (2003).
93. Gascoyne RD, Lamant L, Martin-Subero JI et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102(7), 2568-2573 (2003).
94. Lamant L, Pulford K, Bischof D et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156(5), 1711-1721 (2000).
95. Pillay K, Govender D, Chetty R. ALK protein expression in rhabdomyosarcomas. Histopathology 41(5), 461-467 (2002).
96. Cessna MH, Zhou H, Sanger WG et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 15(9), 931-938 (2002).
97. Evens AM, Gartenhaus RB. Molecular etiology of mature T-cell non-Hodgkins lymphomas. Front. Biosci. 8, D156-D175 (2003).
98. Alonsozana EL, Stamberg J, Kumar D et al. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic γδ T-cell lymphoma. Leukemia 11(8), 1367-1372 (1997).
99. Zettl A, Ott G, Makulik A et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J. Pathol. 161(5), 1635-1645 (2002).
100. Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T-cell acute lymphoblastic leukemia. Cancer Cell 1(1), 75-87 (2002). Unraveling the expression profiles of these diseases, revealing disrupted and prognostically relevant pathways unrelated to chromosomal translocations.
101. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99(2), 409-426 (2002). Comprehensive overview from international leaders in the development of immunohistochemical studies that are paramount to the practice of hematopathology.
102. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. BCL-6 gene mutations in post-transplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92(7), 2294-2302 (1998).